Unknown

Dataset Information

0

Structural basis for the broad and potent cross-reactivity of an N501Y-centric antibody against sarbecoviruses.


ABSTRACT: More than 80% of SARS-CoV-2 variants, including Alpha and Omicron, contain an N501Y mutation in the receptor-binding domain (RBD) of the spike protein. The N501Y change is an adaptive mutation enabling tighter interaction with the human ACE2 receptor. We have developed a broadly neutralizing antibody (nAb), D27LEY, whose binding affinity was intentionally optimized for Y501. This N501Y-centric antibody not only interacts with the Y501-containing RBDs of SARS-CoV-2 variants, including Omicron, with pico- or subnanomolar binding affinity, but also binds tightly to the RBDs with a different amino acid at residue 501. The crystal structure of the Fab fragment of D27LEY bound to the RBD of the Alpha variant reveals that the Y501-containing loop adopts a ribbon-like topology and serves as a small but major epitope in which Y501 is a part of extensive intermolecular interactions. A hydrophobic cleft on the most conserved surface of the RBD core serves as another major binding epitope. These data explain the broad and potent cross-reactivity of this N501Y-centric antibody, and suggest that a vaccine antigenic component composed of the RBD core and a part of receptor-binding motif (RBM) containing tyrosine at residue 501 might elicit broad and potent humoral responses across sarbecoviruses.

SUBMITTER: Jeong BS 

PROVIDER: S-EPMC9714666 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature

altmetric image

Publications

Structural basis for the broad and potent cross-reactivity of an N501Y-centric antibody against sarbecoviruses.

Jeong Bo-Seong BS   Jeon Joon Young JY   Lai Chih-Jen CJ   Yun Hye-Yeoung HY   Jung Jae U JU   Oh Byung-Ha BH  

Frontiers in immunology 20221117


More than 80% of SARS-CoV-2 variants, including Alpha and Omicron, contain an N501Y mutation in the receptor-binding domain (RBD) of the spike protein. The N501Y change is an adaptive mutation enabling tighter interaction with the human ACE2 receptor. We have developed a broadly neutralizing antibody (nAb), D27LEY, whose binding affinity was intentionally optimized for Y501. This N501Y-centric antibody not only interacts with the Y501-containing RBDs of SARS-CoV-2 variants, including Omicron, wi  ...[more]

Similar Datasets

| S-EPMC2981354 | biostudies-literature
| S-EPMC6358714 | biostudies-literature
| S-EPMC10688377 | biostudies-literature
| S-EPMC3411002 | biostudies-literature
2024-11-21 | GSE282247 | GEO
| S-EPMC6402988 | biostudies-literature
| S-EPMC8043460 | biostudies-literature
| S-EPMC7253169 | biostudies-literature
| S-EPMC6096824 | biostudies-literature
| S-EPMC8095199 | biostudies-literature